Domov › Rak dojke › Kalifornija › San Francisco
Klinične študije za Rak dojke v San Francisco, CA
43 študij za Rak dojke išče udeležence na lokacijah v San Francisco in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Vključevanje udeležencevFaza 1/2
- Research Site, San Francisco
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Vključevanje udeležencevFaza 3
- University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Vključevanje udeležencev
- Kaiser Permanente-San Francisco, San Francisco
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Vključevanje udeležencevFaza 2
- University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Vključevanje udeležencevFaza 3
- Clinical Trial Site, San Francisco
- Clinical Trial Site, San Francisco
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Vključevanje udeležencevFaza 3
- Kaiser Permanente, San Francisco
- UCSF Medical Center at Mission Bay, San Francisco
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Vključevanje udeležencevVabljeni zdravi prostovoljci
- University of California San Francisco, San Francisco
Pulsed Electric Field Ablation for Metastatic Breast Cancer
Vključevanje udeležencev
- University of California San Francisco, San Francisco
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Vključevanje udeležencevFaza 3
- UCSF Zuckerberg SF General, San Francisco
- University of California, San Francisco (UCSF), San Francisco
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Vključevanje udeležencevFaza 1
- UCSF Medical Center at Mission Bay, San Francisco
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Vključevanje udeležencevFaza 1/2
- UCSF Helen Diller Family CCC, San Francisco
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Vključevanje udeležencevFaza 1/2
- University of California, San Francisco, San Francisco
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- University of California-San Fransisco, San Francisco
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Vključevanje udeležencevOpazovalna študija
- University of California, San Francisco, San Francisco
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Vključevanje udeležencevFaza 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Vključevanje udeležencevFaza 2
- University of San Francisco, San Francisco
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Vključevanje udeležencevFaza 2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 2
- University of California San Francisco, San Francisco
Generative AI Patient Education Module for Breast Oncology
Vključevanje udeležencev
- University of California, San Francisco, San Francisco
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Vključevanje udeležencevFaza 3
- University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco
E-Mindfulness Approaches for Living After Breast Cancer
Vključevanje udeležencevFaza 3
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Vključevanje udeležencevFaza 2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- UCSF Medical Center at Mission Bay, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Vključevanje udeležencevFaza 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Magnetic Resonance Imaging in Radiotherapy for Breast Cancer
Vključevanje udeležencevOpazovalna študija
- University of California, San Francisco, San Francisco
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
Vključevanje udeležencevFaza 3
- University of California at San Francisco, San Francisco
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Vključevanje udeležencevFaza 2
- University of California San Francisco (UCSF), San Francisco
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Vključevanje udeležencevFaza 2
- UCSF Medical Center-Mission Bay/Benioff Children's Hospital, San Francisco
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Vključevanje udeležencevFaza 2
- University of California San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Vključevanje udeležencev
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Vključevanje udeležencevFaza 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Novel Body Composition Measurements in Association With Outcomes of Breast Reconstruction Reconstruction
Vključevanje udeležencevOpazovalna študija
- University of California, San Francisco
Microbiome and Association With Implant Infections
Vključevanje udeležencevFaza 2
- University of California, San Francisco, San Francisco
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Vključevanje udeležencevOpazovalna študija
- Kaiser Permanente-San Francisco, San Francisco
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Vključevanje udeležencevFaza 2
- University of California San Francisco (Data collection only), San Francisco
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Vključevanje udeležencevFaza 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Vključevanje udeležencevFaza 1
- University of California San Francisco, San Francisco
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
Vključevanje udeležencev
- UCSF Breast Care Center, San Francisco
Patient Care Outreach, Navigation, Technology and Support 2.0
Vključevanje udeležencev
- Zuckerberg San Francisco General Hospital, San Francisco
- University of California, San Francisco, San Francisco
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- University of California, San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, San Francisco
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Vključevanje udeležencevOpazovalna študija
- UCSF Breast Care Center, San Francisco
Študije za Rak dojke v drugih mestih
- New York City, NY136 študij
- Houston, TX126 študij
- Boston, MA112 študij
- Nashville, TN81 študij
- Los Angeles, CA73 študij
- Edison, NJ68 študij
- St. Louis, MO64 študij
- Queens, NY64 študij
- Durham, NC64 študij
- Chicago, IL59 študij
- Philadelphia, PA56 študij
- Dallas, TX55 študij
Druge študije v San Francisco
- Rak prostate45 študij
- Nemalicelični pljučni rak36 študij
- Rak (vse vrste)35 študij
- Srčno popuščanje29 študij
- Metastatski rak28 študij
- Rak pljuč22 študij
- Melanom22 študij
- Rak trebušne slinavke20 študij
- Rak jajčnikov19 študij
- Kolorektalni rak18 študij
- Srčno-žilne bolezni18 študij
- Glioblastom17 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.